84 completed, 16 active not recruiting, 10 recruiting, 10 terminated. 138 Phase 3, 34 Phase 2.
Follow Lysosomal Storage Diseases: new trials by email Literature Review of Lysosomal Storage Diseases trials Research Report on Lysosomal Storage Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 18 | 2027-02-02 | 2026-11-12 |
| The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3) Venglustat, Imiglucerase - Gaucher's Disease Type III | Phase 3 | Not yet recruiting | Sanofi | 18 | 2026-12-11 | 2026-11-10 |
| Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis | Phase 2 / Phase 3 | Not yet recruiting | Azafaros B.V. | 218 | 2026-12-10 | 2026-10-21 |
| Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) Tralesinidase alfa (TA) - MPS IIIB | Phase 3 | Not yet recruiting | Spruce Biosciences | 14 | 2026-12-01 | 2026-09-21 |
| A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease Lucerastat - Fabry Disease | Phase 3 | Recruiting | Idorsia Pharmaceuticals Ltd. | 16 | 2026-12-01 | 2026-11-03 |
| Study of Velaglucerase Beta ERT in Children With Gaucher Disease Velaglucerase beta - Gaucher Disease, Gaucher Disease Type 1 | Phase 3 | Not yet recruiting | CANbridge Life Sciences Ltd. | 10 | 2026-09-16 | 2026-09-29 |
| A Gaucher Disease Gene Therapy Trial With FLT201 FLT201 - Gaucher Disease Type 1 | Phase 3 | Recruiting | Spur Therapeutics | 45 | 2026-04-07 | 2026-10-14 |
| Study of Cannabidiol in Sanfilippo Syndrome Epidiolex, Placebo - Sanfilippo Syndrome, Mucopolysaccharidosis III | Phase 2 / Phase 3 | Recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 35 | 2026-04-01 | 2026-09-15 |
| A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants Migalastat HCl 20 mg - Fabry Disease | Phase 3 | Recruiting | Amicus Therapeutics | 8 | 2026-01-08 | 2026-10-22 |
| RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) RGX-121-3102 - MPS II, Hunter Syndrome (MPS II) | Phase 3 | Active not recruiting | REGENXBIO Inc. | 2 | 2025-11-25 | 2026-06-04 |
| A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease PRX-102 1 mg/kg every two weeks - Fabry Disease | Phase 2 / Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 22 | 2025-07-29 | 2026-08-10 |
| A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis AZ-3102, Placebo - Gangliosidoses, GM2, Gangliosidosis, GM1 | Phase 3 | Active not recruiting | Azafaros B.V. | 75 | 2025-06-30 | 2026-09-22 |
| A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis AZ-3102, Placebo - Niemann-Pick Type C Disease, GM1 Gangliosidosis | Phase 3 | Recruiting | Azafaros B.V. | 147 | 2025-06-30 | 2026-10-27 |
| A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC) Nizubaglustat, Placebo - Niemann-Pick Type C Disease | Phase 3 | Recruiting | Azafaros B.V. | 72 | 2025-06-30 | 2026-10-28 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day - Sanfilippo Syndrome, MPS3 | Phase 2 / Phase 3 | Unknown | Ozlem Goker-Alpan | 10 | 2024-12-01 | 2025-08-20 |
| Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment Idursulfase-IT, Elaprase - Hunter Syndrome | Phase 2 / Phase 3 | Active not recruiting | Takeda | 6 | 2024-03-05 | 2025-11-06 |
| A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT Experimental: OTL-203, Active Comparator: Allo-HSCT - MPS-IH (Hurler Syndrome) | Phase 3 | Active not recruiting | Orchard Therapeutics | 41 | 2023-12-11 | 2025-12-22 |
| A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia | Phase 3 | Completed | QED Therapeutics, a BridgeBio company | 114 | 2023-11-10 | 2026-03-17 |
| An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3 | Phase 2 / Phase 3 | Withdrawn | AVROBIO | 2023-10-01 | 2023-08-09 |
Showing 20 of 138. Sign in to see all of them.
Fabry Disease (30) · Gaucher Disease (28) · Mucopolysaccharidosis II (19) · Sudden Infant Death (12) · Niemann-Pick Disease, Type C (11) · Glycogen Storage Disease Type II (8) · Mucopolysaccharidosis IV (8) · Mucopolysaccharidosis I (7) · Mucopolysaccharidosis III (7) · Gangliosidosis, GM1 (6) · Rare Diseases (6) · alpha-Mannosidosis (6) · Cystinosis (5) · Gangliosidoses, GM2 (5)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (138) · Nutritional and Metabolic Diseases (138) · Metabolism, Inborn Errors (137) · Genetic Diseases, Inborn (135) · Metabolic Diseases (133) · Nervous System Diseases (102) · Brain Diseases (85) · Brain Diseases, Metabolic (85) · Brain Diseases, Metabolic, Inborn (85) · Central Nervous System Diseases (85) · Lysosomal Storage Diseases, Nervous System (85) · Lipid Metabolism Disorders (78) · Lipid Metabolism, Inborn Errors (78) · Lipidoses (78)
migalastat (12) · imiglucerase (8) · larazotide acetate (8) · Glucosylceramidase (7) · agalsidase alfa (7) · agalsidase beta (7) · miglustat (7) · idursulfase (6) · taliglucerase alfa (6) · 2-Hydroxypropyl-beta-cyclodextrin (5) · GAA protein, human (5) · eliglustat (5) · Cysteamine (4) · venglustat (4) · Cyclodextrins (3)
Genzyme, a Sanofi Company (15) · Shire (14) · Amicus Therapeutics (11) · Chiesi Farmaceutici S.p.A. (7) · Sanofi (6) · BioMarin Pharmaceutical (5) · Pfizer (5) · Amgen (4) · Azafaros B.V. (4) · JCR Pharmaceuticals Co., Ltd. (4) · Mandos LLC (4) · Protalix (4) · Ultragenyx Pharmaceutical Inc (4) · ISU Abxis Co., Ltd. (3) · Idorsia Pharmaceuticals Ltd. (3)
United States (87) · United Kingdom (66) · France (51) · Spain (45) · Italy (42) · Canada (41) · Germany (39) · Australia (36) · Argentina (29) · Brazil (27) · Netherlands (26) · Japan (23) · Turkey (Türkiye) (21) · Poland (19) · Belgium (16)
Allan M Lund, MD (2) · Debra Lounsbury (2) · Paul Harmatz, MD (2) · Alexander Schramm (1) · Ali Rabani, Professor (1)
PMID 33874971, PMID 27839979, PMID 39847314, PMID 19775921, PMID 26053270, PMID 27509102, PMID 27657681, PMID 31889231, PMID 32063397, PMID 32994552, PMID 35961250, PMID 37415957, PMID 37915038, PMID 39774103, PMID 41631150, PMID 18729283, PMID 19117887, PMID 20393176, PMID 20730727, PMID 21150784, PMID 21543987, PMID 21586746, PMID 21900191, PMID 22476655, PMID 22929184, PMID 23270487, PMID 23339116, PMID 23531228, PMID 23837440, PMID 24948347, PMID 24950666, PMID 24993530, PMID 25487082, PMID 25688781, PMID 25795794, PMID 25801797, PMID 25819691, PMID 25955246, PMID 26043810, PMID 26185417, PMID 27102949, PMID 27174694, PMID 27241455, PMID 27499018, PMID 27834756, PMID 27839981, PMID 27955919, PMID 28167660, PMID 28535791, PMID 29248359
2015 (5), 2023 (5), 2019 (4), 2008 (3), 2009 (3), 2014 (2), 2018 (2), 2004 (1), 2005 (1), 2016 (1), 2017 (1), 2025 (1)